Acquisition by Camden Partners Strategic Fund Ii A Lp of 5000 shares of Pharming Group at 0.68 subject to Rule 16b-3
PHAR Stock | USD 9.27 0.53 6.06% |
Slightly above 54% of Pharming Group's retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Pharming Group NV suggests that some traders are interested. Pharming Group's investing sentiment overview a quick insight into current market opportunities from investing in Pharming Group NV. Many technical investors use Pharming Group NV stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Pharming |
Filed transaction by Pharming Group NV Other See General Remarks And Fn 1. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Pharming Group's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Pharming Group's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Pharming Group Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Pharming Group can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pharming Group Fundamental Analysis
We analyze Pharming Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Pharming Group is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Pharming Group NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharming Group stock to make a market-neutral strategy. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics with similar companies.
Peers
Pharming Group Related Equities
ACRV | Acrivon Therapeutics, | 8.45 | ||||
FENC | Fennec Pharmaceuticals | 1.32 | ||||
JANX | Janux Therapeutics | 1.15 | ||||
PRTC | PureTech Health | 0.89 | ||||
ANEB | Anebulo Pharmaceuticals | 0.64 | ||||
MOLN | Molecular Partners | 0.36 | ||||
GNTA | Genenta Science | 0.19 | ||||
VRCA | Verrica Pharmaceuticals | 1.14 | ||||
RZLT | Rezolute | 1.39 | ||||
MLYS | Mineralys Therapeutics, | 1.45 | ||||
ELYM | Eliem Therapeutics | 1.90 | ||||
LRMR | Larimar Therapeutics | 2.81 | ||||
OPT | Opthea | 3.32 |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.